HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Drug-Eluting Stents

Subscribe to New Research on Drug-Eluting Stents

Stents that are covered with materials that are embedded with chemicals that are gradually released into the surrounding milieu.

Also Known As:

Drug Coated Stents; Drug Eluting Stents; Drug-Coated Stent; Drug-Eluting Stent; Stent, Drug-Coated; Stent, Drug-Eluting; Stents, Drug Coated; Stents, Drug Eluting; Drug-Coated Stents; Stents, Drug-Coated; Stents, Drug-Eluting

Networked: 1142 relevant articles (76 outcomes, 176 trials/studies) for this Therapy, Comments

Relationship Network

Therapy Context: Research Results

Equipment and Supplies
- Prostheses and Implants: 10106
  - Stents: 17809
    - Drug-Eluting Stents: 1142

Experts

1.	Serruys, Patrick W: 41 articles (01/2010 - 03/2002)
2.	Waksman, Ron: 32 articles (03/2010 - 01/2004)
3.	Park, Seung-Jung: 28 articles (01/2010 - 01/2005)
4.	Colombo, Antonio: 27 articles (03/2009 - 04/2002)
5.	Kim, Young-Hak: 23 articles (01/2010 - 11/2005)
6.	Pichard, Augusto D: 22 articles (03/2010 - 04/2004)
7.	Satler, Lowell F: 21 articles (03/2010 - 04/2004)
8.	Sheiban, Imad: 21 articles (02/2010 - 11/2007)
9.	Hong, Myeong-Ki: 21 articles (02/2010 - 01/2005)
10.	Park, Seong-Wook: 21 articles (01/2010 - 01/2005)

Related Diseases

1.	Coronary Artery Disease (Coronary Atherosclerosis) 02/07/2007 - "Although full metal jacket using drug-eluting stent (DES) for a single coronary artery disease has sparsely been described before, there is no report of safety and efficacy of complete metal jacket from left main (LM) to three major coronary arteries. " 08/01/2006 - "Background: Drug-eluting stents have been shown to be very effective in the treatment of coronary artery disease. " 04/01/2006 - "In coronary artery disease, although drug eluting stents have improved the results of percutaneous coronary intervention, coronary artery bypass grafts have still has an important place in the treatment of severe lesions: multivessel disease, left main and diabetes. " 12/01/2008 - "CONCLUSIONS: Implantation of drug-eluting stents is safe and effective for management of left main coronary artery disease with good immediate and long-term outcomes." 08/01/2008 - "BACKGROUND: Drug-eluting stents (DES) represent a significant improvement in the treatment of coronary artery disease as they decrease restenosis rates by approximately 50% compared with bare-metal stents. " Order ALL the reference details at left...
2.	Thrombosis (Thrombus) 10/01/2008 - "While the risk ofrestenosis has been dramatically reduced by drug-eluting stents, delayed neo-intimal healing has led to a small, but significant occurrence of "late" stent thrombosis. " 07/01/2006 - "Although, drug-eluting stents have significantly reduced angiographic restenosis rate and have improved the clinical outcome, late thrombosis and restenosis remain an important subject of ongoing research. " 08/01/2007 - "Though remarkably effective in reducing this complication, recent data reveal that drug-eluting stents pose a significant risk for late stent thrombosis, an event strongly correlated with discontinuation of anti-platelet therapy. " 02/01/2008 - "Drug-eluting stents (DES) have realized improved clinical results in patients undergoing PCI but are not free of restenosis and are limited by thrombosis, particularly in more complex lesion types. " 02/01/2008 - "There have been major advances in techniques as well as more widespread use of drug-eluting stents; both appear to have contributed to the realization of single-digit target lesion revascularization rates as well as improvement in short-term complications such as stent thrombosis. " Order ALL the reference details at left...
3.	Myocardial Infarction 04/01/2008 - "INTRODUCTION AND OBJECTIVES: Drug-eluting stents (DES) have proven to be effective in reducing the rate of restenosis and have, therefore, been incorporated into the treatment of patients with ST-elevation acute myocardial infarction (STEMI). " 01/01/2007 - "These findings conducted in a 'real world' practice setting in the United States demonstrate that drug-eluting stent implantation for acute ST-elevation myocardial infarction is safe and effective, with a low rate of major adverse cardiac events during mid-term follow-up." 05/07/2009 - "BACKGROUND: There is no consensus regarding the safety and efficacy of drug-eluting stents, as compared with bare-metal stents, in patients with ST-segment elevation myocardial infarction who are undergoing primary percutaneous coronary intervention (PCI). " 06/01/2008 - "The efficacy of bare metal stent implantation for patients with acute myocardial infarction in the drug-eluting stent era." 05/01/2008 - "Safety and efficacy of drug-eluting stent for ST-segment elevation myocardial infarction in an unselected consecutive cohort." Order ALL the reference details at left...
4.	Pathologic Constriction (Stenosis) 02/01/2007 - "In the era of drug-eluting stents that have dramatically reduced the re-stenosis rate, and in the context of the development of emerging modalities like magnetic resonance imaging (MRI) and multislice computed tomography that allow precise and non-invasive diagnosis, it becomes important to question whether and how fluoroscopic-based evaluation of cardiac structure and function shall evolve. " 02/01/2009 - "Urgent coronary angiography showed severe LMCA stenosis caused by extrinsic compression from the pulmonary artery with no other lesions in the coronary arteries; coronary angioplasty was successfully performed with a direct drug-eluting stent implantation that led to a significant improvement of the haemodynamic conditions in the following days. " 01/01/2005 - "With coronary revascularization, drug-eluting stents have significantly decreased the incidence of in-stent stenosis and, therefore, the morbidity of the procedure. " 12/01/2008 - "Data are limited about the relative efficacy of drug-eluting stents (DESs) versus bare-metal stents (BMSs) for the treatment of unprotected left main coronary artery (ULMCA) stenosis. " 01/01/2008 - "BACKGROUND: Improved outcomes of percutaneous coronary interventions (PCI) with drug-eluting stents (DES) have resulted in their expanded use for left main coronary artery (LMCA) stenosis. " Order ALL the reference details at left...
5.	Hyperplasia 11/01/2008 - "In recent years, percutaneous coronary intervention (PCI) with drug eluting stents (DES) to treat de novo coronary lesions has been associated with a significant reduction of neointimal hyperplasia and in-stent restenosis. " 10/06/2004 - "The examination of neointimal hyperplasia in injured animal artery models has helped in our understanding of angioplasty and stenting mechanisms, and as drug-eluting stent (DES) technologies have arrived, they too have been advanced through the study of animal models. " 01/01/2010 - "Drug-eluting stents (DES) improved on the principle of BMS by also delivering drugs locally to inhibit neointimal hyperplasia. " 10/01/2009 - "The antirestenotic efficacy of drug-eluting stent (DES) technology is based on the local delivery and modulated release of cytotoxic drugs targeted at inhibition of neointimal hyperplasia. " 01/01/2010 - "Serial IVUS has demonstrated significant differences in intimal hyperplasia (IH) volume between drug-eluting stent (DES) and bare metal stents (BMS) in recent clinical trials. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Paclitaxel (Taxol)
2.	Sirolimus (Rapamycin)
3.	glucuronyl glucosamine glycan sulfate (Vessel)
4.	Aspirin (Acetylsalicylic Acid)
5.	clopidogrel (Plavix)
6.	Polymers
7.	Glycoproteins (Glycoprotein)
8.	cilostazol (Pletal)
9.	tirofiban (Aggrastat)
10.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)

Related Therapies and Procedures

1.	Stents
2.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
3.	Angioplasty (Angioplasties)
4.	Transplants (Transplant)
5.	Balloon Angioplasty (Angioplasty, Transluminal)

blog comments powered by Disqus

TREATMENT OPTIONS
for Coronary Artery Disease,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 809 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>